Analysts Set MediWound Ltd. (NASDAQ:MDWD) PT at $31.67

by · The Markets Daily

Shares of MediWound Ltd. (NASDAQ:MDWD – Get Free Report) have received a consensus rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $31.6667.

Several brokerages have recently commented on MDWD. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Wall Street Zen cut MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd.

Get Our Latest Stock Analysis on MDWD

Hedge Funds Weigh In On MediWound

Several large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Rhumbline Advisers raised its holdings in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. Marshall Wace LLP bought a new position in shares of MediWound in the 2nd quarter worth about $317,000. Finally, Menora Mivtachim Holdings LTD. bought a new position in shares of MediWound in the 2nd quarter worth about $339,000. 46.83% of the stock is currently owned by institutional investors.

MediWound Price Performance

MDWD opened at $17.22 on Monday. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50. The stock has a market capitalization of $220.59 million, a PE ratio of -8.20 and a beta of 0.13. The firm’s fifty day moving average price is $17.63 and its 200 day moving average price is $17.86.

MediWound (NASDAQ:MDWD – Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. The company had revenue of $1.87 million during the quarter, compared to analyst estimates of $2.09 million. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. On average, equities research analysts forecast that MediWound will post -2.66 earnings per share for the current fiscal year.

About MediWound

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

Further Reading